Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › allopurinol

allopurinol

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of allopurinol

41 trials tracked of allopurinol: 21 in phase 3 or 4 and 7 with published results. The most-cited published study has 890 citations.

41Trials tracked
21Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 6 Phase 3 15 Phase 2 14 Phase 1 3 Other / NA 3
  1. Phase 3 Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) Completed · 890 cited
  2. Phase 3 A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes Completed · 356 cited
  3. Phase 3 Combining Lesinurad With Allopurinol in Inadequate Responders Completed · 180 cited
  4. Phase 3 Combining Lesinurad With Allopurinol in Inadequate Responders Completed · 166 cited
  5. Phase 4 Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion Completed · 83 cited
  6. Phase 3 Center of Research Translation (CORT) Project 2 Completed · 51 cited
Show 35 more trials
  1. Phase 4 Allopurinol Add-on Treatment for Refractory Mania Completed · 28 cited
  2. Phase 4 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Completed
  3. Phase 4 Does Allopurinol Prolong a Treated, Acute Gout Flare? Completed
  4. Phase 4 Allopurinol Outcome Study Completed
  5. Phase 4 Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol Completed
  6. Phase 3 Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function Completed
  7. Phase 3 Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome Completed
  8. Phase 3 Safety and Efficacy of Oral Febuxostat in Subjects With Gout Completed
  9. Phase 3 Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. Completed
  10. Phase 3 Efficacy and Safety of Oral Febuxostat in Participants With Gout Completed
  11. Phase 3 Impact of Diabetes on Left Ventricular Remodeling Completed
  12. Phase 3 Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Completed
  13. Phase 3 Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies Completed
  14. Phase 3 Uric Acid and Hypertension in African Americans Completed
  15. Phase 3 Febuxostat Versus Allopurinol Control Trial in Subjects With Gout Completed
  16. Phase 2 Intravenous Allopurinol in Heart Failure Completed
  17. Phase 2 Study of Verinurad in Heart Failure With Preserved Ejection Fraction Completed
  18. Phase 2 Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones Completed
  19. Phase 2 Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels Completed
  20. Phase 2 Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients Completed
  21. Phase 2 S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed
  22. Phase 2 Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 Completed
  23. Phase 2 Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia Completed
  24. Phase 2 Study of Cardiovascular Disease and Obstructive Sleep Apnea Completed
  25. Phase 2 Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia Completed
  26. Phase 2 Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid Completed
  27. Phase 2 A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study) Completed
  28. Phase 2 Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia Completed
  29. Phase 2 A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia Completed
  30. Phase 1 Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers Completed
  31. Phase 1 A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart Completed
  32. Phase 1 Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant Completed
  33. N/A Uric Acid and the Endothelium in CKD Completed
  34. N/A A Controlled Study of Uric Acid on the Progression of IgA Nephropathy Completed
  35. N/A Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol Completed

Showing the 41 most-cited and recently-updated of 41 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review discusses Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis risks from various medications
Drug Pipeline Sys. Review
Narrative review discusses Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis risks from various medications A review explains which drugs may cause severe skin reactions like Stevens-Johnson Syndrome
This narrative review examines Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis associated with antibiotics, antiepileptics, allopuri…
This review looks at medications linked to rare but dangerous skin conditions. It helps doctors and patients understand the risks.
Frontiers Jun 2, 2026
Treat-to-target strategy improves gout remission vs symptom-driven care
Rheumatology RCT
Treat-to-target strategy improves gout remission vs symptom-driven care A new gout treatment strategy is changing outcomes
This open-label RCT in 308 adults with gout and hyperuricaemia found that a treat-to-target strategy (urate-guided titration) led to higher …
Many people with gout stay in pain despite treatment, but aiming for a specific uric acid level nearly doubles the chance of remission.
May 3, 2026